CliffBio
small molecule

TREXIMET

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

Loss of exclusivityApril 2026latest FDA-listed patent expiry
CompanyCurrax Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameTREXIMET
Active ingredientNAPROXEN SODIUM; SUMATRIPTAN SUCCINATE
Strength60MG;EQ 10MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMay 2015
Marketing statusDISCN

Listed patents

PatentExpiresType
7332183*PEDApril 2026—
7332183October 2025product

More from Currax Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TREXIMET patent cliff — loss of exclusivity April 2026 | CliffBio